Playing both sides of trade war, pharma companies are asking for certain compensations for scientific innovation and a ...

Pharma companies are leveraging the United States’ threat of tariffs on drug imports to push for policy changes in the EU. | ...

Abrysvo is now approved in the EU for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease caused by RSV.

Pfizer (PFE) announced that the European Commission has issued a decision amending the marketing authorization for Abrysvo, the company’s bivalent respiratory syncytial virus prefusion F vaccine ...

April 1 (Reuters) - The European Commission approved Pfizer's (PFE.N), opens new tab respiratory syncytial virus vaccine for the prevention of lower respiratory tract disease caused by RSV in ...

Nearly three dozen global pharmaceutical companies, in a letter to the head of the European Commission, demanded help to ...

Pfizer Inc. has announced that the European Commission (EC) has issued a decision amending the marketing authorization for ABRYSVO, the company’s bivalent respiratory syncytial ...

ABRYSVO is the first and only RSV vaccine approved in the European Union (EU ... Executive Vice President, Pfizer. “With an indication that also includes pregnant individuals between weeks ...

Pfizer Inc. has announced the company has discontinued the development of danuglipron (PF-06882961), an oral glucagon-like ...

PARIS (Reuters) -Nearly three dozen global pharmaceutical companies, in a letter to the head of the European Commission, ...

NEW YORK, April 01, 2025--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has issued a decision amending the marketing authorization for ABRYSVO ®, the ...